ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc

<< Previous

Bullboard Posts

Next >>

Post by Gbathaton Mar 08, 2024 6:51pm

148 Views

Post# 35923851

J&J seems like they'd be a good partner

Johnson & Johnson had $23B in cash on hand as of Dec 2023.

They lack an anti-amyloid candidate but have an active AD research unit that has an anti-tau approach.

They are interested in neuroscience opportunities. J&J CEO Joaquin Duato said on the company’s fourth-quarter earnings call that he sees additional dealmaking “opportunities” in neuroscience and immunology. He reiterated an often-made point that J&J is agnostic to sector or size but prefers to stay in carved-out lanes.

https://www.fiercebiotech.com/biotech/jj-sees-deal-opportunities-neuroscience-and-immunology-post-ambrx-buy

<< Previous

Bullboard Posts

Next >>

From now on, dynaCERT instead of Bitcoin or NVIDIA?